Syapse, a San Francisco, CA-based provider of precision oncology solutions announced $30 million in new equity funding to accelerate the creation and use of real-world evidence (RWE) in oncology led by Revelation Alpine, LLC, with participation from existing investors including Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Roche Finance Ltd, Safeguard Scientifics and Social Capital. Revelation Alpine’s Managing Partner Zack Scott, MD will join the Syapse Board of Directors.
RWE Use to Support Precision Medicine & Oncology
Founded in 2008, Syapse’s oncology software platform enables oncologists to practice precision medicine consistently across large health systems. The Syapse Data Sharing Network puts the power of real-world evidence in the hands of oncologists, enabling physicians to view treatments and outcomes for patients across the country and use this information to improve treatment decisions for their own patients.
Derive RWE From Multiple Sources including EHRs
By connecting with electronic health records (EHRs), data warehouses, registries, and other sources, Syapse is able to extract complex clinical data such as diagnosis and staging, pathology and radiology reports, treatment and outcomes, demographics, and more. Syapse also captures genomic and other molecular test results as structured data through direct integration with molecular diagnostics labs. Additionally, Syapse applies a data quality improvement framework that uses a combination of manual abstraction by highly trained medical data professionals and machine learning to create a comprehensive patient record.
Syapse collaborates with life sciences companies to provide insights from real-world data through its portfolio of products to support research and product development, clinical trials patient matching, real-world evidence regulatory filings, and monitoring of commercially approved products. Syapse supports health systems with insights to support health systems’ large-scale precision medicine programs through integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions. These programs are supported by insights derived from the real-world data in the Syapse Learning Health Network and enable solutions such as clinical trial matching for targeted therapies, testing recommendations, and outcomes research.
Recent Traction
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Last month, Syapse announced data from its research collaboration with the Office of Clinical Pharmacology (OCP) within the FDA Center for Drug Evaluation and Research (CDER), and Advocate Aurora Health were presented during the Clinical Plenary Session of the American Association for Cancer Research (AACR) Virtual Annual Meeting. Titled, “Pneumonitis incidence in patients with non-small cell lung cancer treated with immunotherapy or chemotherapy in clinical trials and real-world data,” this study demonstrates how the Syapse Learning Health Network is advancing the development of real-world evidence in a number of important research areas, including safety outcomes.
“We are incredibly proud of the partnerships we have developed and are grateful for the support of our industry-leading investors who share in our vision of tapping into the power of real-world data to accelerate the development and delivery of innovative new cancer therapies,” said Ken Tarkoff, CEO, Syapse.
Source: HIT Consultant
